Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Director departure
Appointed director
CorMedix Inc. (CRMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2023 Financial Results and Provides Business Update"
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/29/2022 8-K Quarterly results
Docs: "+++++++++ 3 CORMEDIX INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS"
11/09/2021 8-K Quarterly results
Docs: "+++++++++ CORMEDIX INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
08/12/2021 8-K Quarterly results
Docs: "+++++++++ CorMedix Inc. and SubsidiarIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Three Months Ended June 30, For the Six Months Ended June 30, 2021 2020 2021 2020 Revenue: Net sales $ 8,191 $ 16,443 $ 96,451 $ 90,498 Cost of sales Gross profit 20,686 22,797 Operating Expenses: Research and development Selling, general and administrative Total Operating Expenses Loss From Operations Other Income : Interest income 3,340 38,603 7,014 102,282 Foreign exchange transaction gain Interest expense, including amortization of debt discount - Total Other Income 22,972 Loss before income taxes Tax benefit 1,250,186 5,169,395 1,250,186 5,169,395 Net Loss Other Comprehensive Income : Unrealized gain from investments 13,853 8,221 Foreign currency ..."
05/13/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "+++++++++ 3 CORMEDIX INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "CORMEDIX INC. REPORTS First QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
03/16/2020 8-K Quarterly results
Docs: "+++++++++ 3 CORMEDIX INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS"
08/13/2019 8-K Quarterly results
Docs: "+++++++++ 3 CorMedix Inc. and Subsidiary CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Three Months Ended June 30, For the Six Months Ended June 30, 2019 2018 2019 2018 Revenue: Net sales $ 35,266 $ 7,551 $ 198,958 $ 30,760 Cost of sales Gross profit 14,138 Operating Expenses: Research and development Selling, general and administrative Total Operating Expenses Loss From Operations Other Income : Interest income 95,964 10,196 154,785 24,971 Foreign exchange transaction gain 5,043 Interest expense, including amortization of debt discount - Total Other Income 15,239 18,944 Loss before income taxes Tax benefit 5,060,778 - 5,060,778 - Net Loss Other Comprehensive Income : Unrealized gain from investments 8,846 - 7,839 - Foreign currency trans..."
05/13/2019 8-K Quarterly results
Docs: "CORMEDIX INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – May 13, 2019 – CorMedix Inc. , a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business events. Recent Corporate and Clinical Highlights: ● Announced that the Company has completed the statistical analyses of data and additional information requested by FDA for the primary and secondary efficacy endpoints of the Company’s LOCK-IT-100 clinical study. These analyses support the strong topline ..."
03/14/2019 8-K Quarterly results
Docs: "CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – Mar. 14, 2019 – CorMedix Inc. , a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the fourth quarter and full-year ended December 31, 2018 and provided an update on recent business events. The Company also announced today that its Board of Directors has approved a one-for-five reverse stock split of its common stock that is scheduled to become effective before trading opens on March 26, 2019, after which time the CorMedix com..."
03/19/2018 8-K Quarterly results
Docs: "CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights: ● 28 cases of catheter-related bloodstream infections identified by the Clinical Adjudication Committee, triggering the interim analysis in the Phase 3 LOCK-IT-100 trial; ● Over 750 subjects enrolled to date in its multi-center Phase 3 LOCK-IT-100 trial in Neutrolin for hemodialysis patients with central venous catheters; ● Granted orphan drug designation by the Food and Drug Administration for taurolidine in the treatment of neuroblastoma. Anticipated Milestones: ● Interim efficacy analysis of the LOCK-IT-100 study is anticipated to be completed during the s..."
11/09/2017 8-K Quarterly results
Docs: "CorMedix Inc. Reports Third Quarter Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights: ● Executed $5 million combined Securities Purchase and Backstop Agreement ● Continued to advance Phase 3 LOCK-IT 100 clinical study of Neutrolin®, surpassing original enrollment target of 632 patients ● Awarded grant funding from the National Institutes of Health to develop antimicrobial hydrogel to treat severe burns ● Presented in vitro data demonstrating susceptibility of deadly fungal pathogen Candida auris to taurolidine at two global infectious disease conferences ● Relocated corporate headquarters; Sublease agreement allows rent-free occupancy until June 2020 ..."
08/09/2017 8-K Quarterly results
Docs: "CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights: ● Implemented several key FDA-agreed changes to the LOCK-IT-100 trial designed to enhance event capture and significantly reduced the number of events required to complete the study ● Hosted R&D Day to announce advances to the taurolidine-based therapeutic and medical device pipeline ● Appointed Mehmood Khan, M.D., Steven Lefkowitz, and Gary Gelbfish, M.D., to the Board of Directors; Elected Myron Kaplan Chairman of the Board of Directors ● Generated initial revenue via Hemotech stocking of distribution channels in France; European commercialization efforts continue ● Si..."
05/10/2017 8-K Form 8-K - Current report
03/17/2017 8-K Form 8-K - Current report
11/10/2016 8-K Quarterly results
Docs: "CorMedix Inc. Reports Third Quarter 2016 Financial Results and Provides Business Updates Conference Call Today at 4:30 p.m. Eastern Time Bedminster, NJ – November 10, 2016 – CorMedix Inc. , a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2016, and highlighted recent business updates. The Company will host a conference call today at 4:30 p.m. Eastern Time. Key Business and Financial Updates: Corporate: ● Appointed former Lilly and UCB executive Khoso Baluch as CEO, bringing >30 years of operational and product launch experience, both U.S. and internationally ● Entered into c..."
05/11/2016 8-K Form 8-K - Current report
03/16/2016 8-K Form 8-K - Current report
08/15/2013 8-K Quarterly results
Docs: "Press release"
03/27/2013 8-K Form 8-K - Current report
03/19/2012 8-K Form 8-K - Current report
11/10/2011 8-K Form 8-K - Current report
08/09/2011 8-K Form 8-K - Current report
05/10/2011 8-K Form 8-K - Current report
03/14/2011 8-K Form 8-K - Current report
11/09/2010 8-K Form 8-K - Current report
08/12/2010 8-K Form 8-K - Current report
05/12/2010 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy